Brief: DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
13/05/2025 21:33
May 13 (Reuters) - DiaMedica Therapeutics Inc DMAC.O: DIAMEDICA THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS DIAMEDICA THERAPEUTICS INC: CASH RUNWAY INTO Q3 2026 DIAMEDICA THERAPEUTICS- TOPLINE DM199 PHASE 2 PART 1A RESULTS EXPECTED IN NEAR TERM AND PHASE 2 PART 1B EXPECTED TO INITIATE IN Q3 2025 Source text: ID:nBw3TprSJa Further company coverage: DMAC.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program